Kura Oncology published early clinical data on darlifarnib (a potential KRAS inhibitor-enabling agent) in combination with Bristol Myers Squibb’s Krazati (adagrasib). The company reported response rates of up to 69% for the combination in the dataset shared. The update positions darlifarnib as an effort to broaden and improve responses to KRAS inhibition, building on the clinical visibility of Krazati in KRAS-mutant cancers. Combination strategies remain a central approach in KRAS-driven oncology due to resistance mechanisms that often emerge with monotherapy. As with early readouts, the next gating item for the program will be durability, safety, and whether activity translates into statistically meaningful endpoints in later-stage studies. Investors will also watch how patient selection and biomarker context influence the range of response rates reported.